Veracyte Inc. Common Stock (VCYT)
Stock · NASDAQ · Health Care
$43.15as of 10/16/2026
Price chart
Active signals
VCYT Signal Track Record
How signals performed across all stocks →What VCYT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 27 | +3.0% | 56% | September 24, 2026 |
| Bollinger Band Breakout | 22 | +5.8% | 64% | September 24, 2026 |
| Bollinger Band Breakdown | 20 | +4.0% | 65% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 19 | -4.0% | 47% | September 4, 2026 |
| Any 20-session window (baseline) | +0.8% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diag…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 755
- Website
- www.veracyte.com/
Fundamentals
- 1-day range
- $42.83$45.75
- Market cap
- $3.71B
- P/E (trailing)
- 31.17
- P/E (forward)
- 22.16
- EPS (trailing)
- $1.40
- Dividend yield
- —
- Beta
- 1.99
- Avg. volume
- 1.37M
How Veracyte Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Veracyte Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VCYTVeracyte Inc. Common Stock$43.12▼ 2.86%Market cap $3.71BP/E 31.17$29.46$60.91
- CONConcentra Group Holdings Parent Inc. Common Stock$38.54▼ 1.56%Market cap $3.91BP/E 24.09$18.55$38.07
- BLLNBillionToOne Inc. Class A Common Stock$98.12▼ 4.49%Market cap $4.22BP/E 128.54$61.96$150.44
- CELCCelcuity Inc. Common Stock$56.58▼ 6.17%Market cap $4.55BP/E —$46.51$151.02
- ACHCAcadia Healthcare Company Inc. Common Stock$29.98▼ 3.41%Market cap $2.86BP/E —$11.43$35.83
- ALHCAlignment Healthcare Inc. Common Stock$8.28▲ 1.60%Market cap $2.78BP/E 41.54$6.01$25.12
- GRALGRAIL Inc. Common Stock$117.81▼ 13.03%Market cap $2.72BP/E —$41.5$166.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VCYT Veracyte Inc. Common Stock | $3.71B | 31.17 | $43.12 | ▼ 2.86% | $29.46$60.91 |
| CON Concentra Group Holdings Parent Inc. Common Stock | $3.91B | 24.09 | $38.54 | ▼ 1.56% | $18.55$38.07 |
| BLLN BillionToOne Inc. Class A Common Stock | $4.22B | 128.54 | $98.12 | ▼ 4.49% | $61.96$150.44 |
| CELC Celcuity Inc. Common Stock | $4.55B | — | $56.58 | ▼ 6.17% | $46.51$151.02 |
| ACHC Acadia Healthcare Company Inc. Common Stock | $2.86B | — | $29.98 | ▼ 3.41% | $11.43$35.83 |
| ALHC Alignment Healthcare Inc. Common Stock | $2.78B | 41.54 | $8.28 | ▲ 1.60% | $6.01$25.12 |
| GRAL GRAIL Inc. Common Stock | $2.72B | — | $117.81 | ▼ 13.03% | $41.5$166.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Programbenzinga · 10/16/2026
- ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/YYahoo · 10/9/2026
- Reasons to Hold Veeva Systems Stock in Your Portfolio for NowYahoo · 10/9/2026
- Veracyte (VCYT) Stock Still Looks Cheap As Its 107% Run ContinuesYahoo · 10/9/2026
- Is it the Right Time to Add Phibro Stock to Your Portfolio?Yahoo · 10/8/2026
- Smith+Nephew Launches CARTIHEAL Implant Across Key European MarketsYahoo · 10/8/2026
- Bruker Gains 66.3% in a Year: What's Driving the Rally?Yahoo · 10/8/2026
- Reasons to Hold HealthEquity Stock in Your Portfolio for NowYahoo · 10/7/2026
- Veeva's DQS Scales Data Automation Across 1,000+ Clinical StudiesYahoo · 10/7/2026
Insider Activity
Insider Actions →- John Leite · September 21, 2026 · Sale4.0K @ $40
- Jens Holstein · September 14, 2026 · Sale5.0K @ $40.95
- Phillip G. Febbo · September 4, 2026 · Sale2.7K @ $43.66
- Phillip G. Febbo · September 4, 2026 · Sale10.4K @ $42.89
- Annie McGuire · September 4, 2026 · Sale1.1K @ $43.67
- Annie McGuire · September 4, 2026 · Sale2.2K @ $42.79
- Rebecca Chambers · September 4, 2026 · Sale1.2K @ $43.71
- Rebecca Chambers · September 4, 2026 · Sale2.5K @ $42.81
- John Leite · September 2, 2026 · Tax Withholding4.0K @ $44.88
- Annie McGuire · September 2, 2026 · Tax Withholding3.2K @ $44.88
- Rebecca Chambers · September 2, 2026 · Tax Withholding3.6K @ $44.88
- Phillip G. Febbo · September 2, 2026 · Tax Withholding3.6K @ $44.88
- Jonathan Wygant · September 2, 2026 · Tax Withholding1.4K @ $44.88
- Marc Stapley · September 2, 2026 · Tax Withholding8.8K @ $44.88
- Muna Bhanji · September 1, 2026 · Sale1.9K @ $42.97
Institutional Ownership
March 31, 2026
- Total shares held
- 82.63M
- Total value held
- $2.59B
- Institutional holders
- 326
- Unknown13.17M
- Unknown7.76M
- Unknown5.50M
- Unknown5.04M
- Unknown3.53M
- Unknown3.05M
- Unknown2.88M
- Unknown2.56M
- Unknown2.12M
- Unknown1.96M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise
Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise. Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.